A Study to Explore the Reasonable Dosage and Evaluate the Efficacy, Safety and Tolerability of HLX10 and HLX04 with or Without HLX53 in Untreated, Locally Advanced or Metastatic Hepatocellular Carcinoma Patients.
Clinical trial NCT06349980 · RECRUITING
Trial details
- NCT number
- NCT06349980
- Sponsor
- Shanghai Henlius Biotech
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-08-05
- Primary completion
- 2027-02-10
- Enrollment
- 117
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.